Puma Biotechnology Inc.'s innovative "basket trial" of its neratinib in a wide variety of cancers highlights the drug's potential beyond breast cancer, but also shows the challenges of studying patients according to mutations, rather than tumor type.
The company presented results for neratinib, an irreversible pan-HER targeting tyrosine kinase inhibitor, as a monotherapy in the Phase II SUMMIT study of multiple solid tumor types with HER2- and HER3-activating mutations on April
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?